Germany Pushes Back on Online Cannabis Prescriptions – A Turning Point for Telemedicine Startups?

The pressure is rising. On Tuesday, the Federal Chamber of Pharmacists (BAK) issued a formal resolution criticizing the increasing number of medical cannabis prescriptions issued through online platforms without personal doctor-patient contact. The move reflects a growing political and professional backlash against digital prescription models that operate with minimal diagnostic effort.

According to the resolution, “the issuance of prescriptions is usually carried out without a personal doctor-patient consultation, often solely based on standardized online questionnaires with minimal diagnostic depth.” The core concern: medical decisions are being reduced to “a simple ordering process by the user,” undermining the legal framework of prescription-only medicine and eroding public trust in medical oversight.

Dr. Armin Hoffmann, president of the BAK, stated: “The supply of prescription-only medicines such as medical cannabis must not be subjected to the commercial interests of digital trading platforms.”

The resolution, endorsed by all 17 presidents of Germany’s state pharmacist chambers, calls on regulators to intervene. It also aligns with the agenda of the Health Ministers’ Conference (GMK), which opened today in Weimar. Online prescriptions—particularly for medical cannabis—will be discussed in detail, reflecting growing concern across the healthcare sector.

For cannabis-focused telemedicine platforms, the message is clear: a policy shift is looming. While no binding legislation has been passed yet, mounting public and institutional scrutiny suggests that mandatory personal consultations for cannabis prescriptions could soon become law.

Platforms operating on automated workflows—driven by digital forms and limited remote interactions—face increased risk. If their core model depends on low-barrier access and rapid online approvals, they may soon need to rebuild critical parts of their compliance architecture.

On the other hand, hybrid models that integrate digital tools with local medical services may find themselves in a stronger position. Those investing now in medical documentation, consultation standards, and audit-proof infrastructure will be better prepared to meet the regulatory standards of tomorrow.

The BAK concludes with a clear appeal: “We call on political actors and supervisory authorities to secure the health of patients by consistently strengthening patient-centered, medically responsible structures.”

My Conclusion:
Germany’s medical cannabis market is maturing—and with that comes stricter oversight. Digital platforms are no longer flying under the radar. This is not the end of cannabis telemedicine, but a strategic turning point. For startups and investors, the focus must now shift from speed to sustainability, from reach to responsibility.

Scroll to Top